Off air

Continuing story · 1 report

Novo Nordisk's lawsuit over Eli Lilly GLP-1 ads

First aired Latest aired

DevelopingNext check : Further court proceedings or a resolution of the case.

Where it stands

Novo Nordisk has sued Eli Lilly in federal court, alleging its direct-to-consumer GLP-1 drug ads make false and misleading dosing comparisons; Lilly says the ads are truthful. No court ruling, settlement or other resolution is reported, so the case remains open.

Story trackerDay 1

1 report11 outlets11 sources1 video

  • No dated events yet
    1. Update 1Four Drugs, One Courtroom: Novo Nordisk Takes Eli Lilly to Trial Over GLP-1 Ads

    The story so far

    1. Update 1

      Four Drugs, One Courtroom: Novo Nordisk Takes Eli Lilly to Trial Over GLP-1 Ads

      A New Jersey federal complaint says Lilly's Zepbound and Mounjaro ads stack the dosing deck against Wegovy and Ozempic. The market they share is reshaping the industry.

      Still open after this report

      • Any verbatim Lilly on-the-record statement beyond the general "truthful and based on the best available scientific evidence" framing. The source file does not include one.
      • How the court will treat the question of which doses are properly comparable, and which clinical trials it considers current.
      • Whether the case produces a settlement, a ruling on the injunction, or a long discovery fight.

    History

    1. Opened1 report

    Who's involved

    Places

    • CopenhagenCopenhagen, Denmark1 report
    • IndianapolisIndianapolis, IN, USA1 report
    • US District Court for the District of New Jersey50 Walnut St #4015, Newark, NJ 07102, USA1 report

    Every outlet we read on this story

    11 sources11 outlets1 video